|Molar mass||364.41 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Pafuramidine (formulated as the maleic acid salt pafuramidine maleate) is an experimental drug for the treatment of pneumocystis pneumonia (PCP). In 2006, pafuramidine was given orphan drug status by the US Food and Drug Administration for PCP in patients with HIV/AIDS. Preliminary clinical trials indicated that pafuramide was effective against pneumocystis pneumonia and had the potential for fewer side effects than the standard treatment with trimethoprim/sulfamethoxazole (TMP-SMX).
- "US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP". Drugs.com. November 21, 2006.
- Chen D, Marsh R, Aberg JA (2007). "Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals". Expert review of anti-infective therapy 5 (6): 921–8. doi:10.1586/14787184.108.40.2061. PMID 18039076.
- "Pafuramidine maleate (DB289)". Swiss Tropical and Public Health Initiative.
- Harrill AH, Desmet KD, Wolf KK, Bridges AS, Eaddy JS, Kurtz CL, Hall JE, Paine MF, Tidwell RR, Watkins PB (2012). "A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models". Toxicol. Sci. 130 (2): 416–26. doi:10.1093/toxsci/kfs238. PMC 3498743. PMID 22940726.